mardi 24 novembre 2015

Onco Actu du 24 novembre 2015

1. Biologie

‘Drivers’ and ‘Passengers’: who’s in charge? [The Darwin Cancer Blog]

2.11 Etiologie - Alimentation

UK bacon and sausages sales hit by cancer link: report [Reuters]

5.10 Traitements - Essais

Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC™ in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International Congress [Exelixis]

5.12 Immunothérapies

Roche's blockbuster-hopeful immunotherapy shows promise in skin cancer [FierceBiotech]

5.2 Pharma

Genmab Announces Ofatumumab Phase III Study in Follicular Lymphoma to be Stopped Following Planned Interim Analysis [Genmab]

XBiotech Provides Update on Phase III COncology Study in Europe [XBiotech]

5.2.2 Pharma - Fusions & Acquisitions

Pfizer and Allergan to Combine [Pfizer]

Pfizer-Allergan [In the Pipeline]

Pfizer-Allergan deal could hurt R&D, increase drug costs [STAT]

Merger Math: Is There Anything Left For Pfizer To Cut At Allergan? [Forbes]

5.3.4 Traitements - AMM (FDA, EMA)

FDA approves Opdivo to treat advanced form of kidney cancer [FDA]

BMS racks up another Opdivo approval after FDA makes quick decision [FierceBiotech]

Two New Therapeutics Approved For Treating Multiple Myeloma [CANCER RESEARCH Catalyst]

European Medicines Agency Recommends Granting a Marketing Authorisation for Asparaginase and Pegaspargase [ESMO]

FDA Approves Nivolumab for the Treatment of Advanced Renal Cell Cancer [ESMO]

Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma [BMS]

6.10 Politiques

Health and economic growth will suffer without commitment to science budget says Cancer Research UK [Cancer Research UK]